ZWJ Investment Counsel’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$972K Buy
16,867
+603
+4% +$34.6K 0.03% 132
2026
Q1
$986K Hold
16,264
0.04% 121
2025
Q4
$877K Sell
16,264
-226
-1% -$10.9K 0.03% 125
2025
Q3
$744K Buy
16,490
+36
+0.2% +$1.68K 0.03% 130
2025
Q2
$762K Sell
16,454
-1,266
-7% -$62.1K 0.03% 126
2025
Q1
$1.08M Sell
17,720
-581
-3% -$33.9K 0.04% 117
2024
Q4
$1.04M Sell
18,301
-92
-0.5% -$5.14K 0.04% 115
2024
Q3
$952K Sell
18,393
-2,214
-11% -$104K 0.04% 116
2024
Q2
$856K Buy
20,607
+412
+2% +$18.4K 0.04% 118
2024
Q1
$1.1M Sell
20,195
-33
-0.2% -$1.68K 0.05% 105
2023
Q4
$1.04M Sell
20,228
-170
-0.8% -$8.92K 0.05% 103
2023
Q3
$1.18M Sell
20,398
-261
-1% -$16K 0.07% 100
2023
Q2
$1.32M Sell
20,659
-550
-3% -$36.9K 0.07% 97
2023
Q1
$1.47M Sell
21,209
-284
-1% -$20K 0.08% 93
2022
Q4
$1.55M Buy
21,493
+25
+0.1% +$1.89K 0.09% 92
2022
Q3
$1.53M Hold
21,468
0.1% 92
2022
Q2
$1.65M Buy
21,468
+4,232
+25% +$322K 0.1% 89
2022
Q1
$1.26M Sell
17,236
-100
-0.6% -$6.71K 0.07% 96
2021
Q4
$1.08M Sell
17,336
-1,400
-7% -$82.1K 0.06% 99
2021
Q3
$1.11M Hold
18,736
0.06% 96
2021
Q2
$1.25M Sell
18,736
-3,670
-16% -$239K 0.07% 96
2021
Q1
$1.41M Sell
22,406
-51,851
-70% -$3.23M 0.09% 91
2020
Q4
$4.61M Buy
74,257
+1,147
+2% +$70.5K 0.31% 58
2020
Q3
$4.41M Sell
73,110
-3,355
-4% -$202K 0.35% 54
2020
Q2
$4.5M Sell
76,465
-125,694
-62% -$7.52M 0.39% 49
2020
Q1
$11.3M Sell
202,159
-4,157
-2% -$254K 1.01% 36
2019
Q4
$13.2M Buy
206,316
+192,528
+1,396% +$11M 0.89% 40
2019
Q3
$699K Buy
13,788
+1,224
+10% +$57.5K 0.05% 99
2019
Q2
$570K Sell
12,564
-316
-2% -$14.7K 0.04% 105
2019
Q1
$615K Sell
12,880
-2,296
-15% -$114K 0.05% 102
2018
Q4
$789K Buy
15,176
+3,209
+27% +$172K 0.07% 90
2018
Q3
$743K Sell
11,967
-243
-2% -$14.4K 0.06% 93
2018
Q2
$676K Sell
12,210
-500
-4% -$27K 0.06% 94
2018
Q1
$804K Buy
12,710
+444
+4% +$28.6K 0.07% 86
2017
Q4
$752K Hold
12,266
0.06% 132
2017
Q3
$782K Sell
12,266
-3,700
-23% -$216K 0.06% 123
2017
Q2
$890K Sell
15,966
-3,991
-20% -$217K 0.07% 117
2017
Q1
$1.08M Buy
19,957
+4,233
+27% +$232K 0.09% 108
2016
Q4
$919K Sell
15,724
-378
-2% -$20.7K 0.09% 90
2016
Q3
$868K Buy
16,102
+427
+3% +$27.4K 0.09% 89
2016
Q2
$1.15M Sell
15,675
-475
-3% -$33.6K 0.12% 83
2016
Q1
$1.03M Buy
16,150
+90
+0.6% +$5.68K 0.11% 83
2015
Q4
$1.1M Sell
16,060
-20
-0.1% -$1.32K 0.12% 85
2015
Q3
$952K Sell
16,080
-133
-0.8% -$8.44K 0.11% 82
2015
Q2
$1.08M Sell
16,213
-49
-0.3% -$3.23K 0.11% 81
2015
Q1
$1.05M Hold
16,262
0.11% 78
2014
Q4
$960K Sell
16,262
-15
-0.1% -$846 0.1% 83
2014
Q3
$833K Sell
16,277
-311
-2% -$15.5K 0.09% 83
2014
Q2
$805K Buy
16,588
+3,811
+30% +$188K 0.09% 84
2014
Q1
$664K Sell
12,777
-700
-5% -$37.2K 0.08% 91
2013
Q4
$717K Sell
13,477
-355
-3% -$18.1K 0.08% 86
2013
Q3
$640K Sell
13,832
-548
-4% -$24.1K 0.08% 88
2013
Q2
$643K Buy
+14,380
New +$624K 0.09% 87

Other funds holding BMY

ZWJ Investment Counsel's BMY Position: Q2 2026 in Review

ZWJ Investment Counsel increased its Bristol-Myers Squibb (BMY) stake by 3.7% in Q2 2026, buying an estimated $34.6K and bringing the position to 16,867 shares worth $972K. The position accounts for 0.03% of the portfolio, ranked #132.

ZWJ Investment Counsel first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $13.2M in Q4 2019. 1,086 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • ZWJ Investment Counsel held 16,867 shares of Bristol-Myers Squibb worth $972K as of Q2 2026.
  • ZWJ Investment Counsel bought 603 Bristol-Myers Squibb shares in Q2 2026, an estimated $34.6K.
  • Bristol-Myers Squibb made up 0.03% of ZWJ Investment Counsel's portfolio in Q2 2026, its #132 holding.
  • ZWJ Investment Counsel first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • ZWJ Investment Counsel's Bristol-Myers Squibb position peaked at $13.2M in Q4 2019.
  • 1,086 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on ZWJ Investment Counsel's 13F filing for Q2 2026, filed 16 Jul 2026.